| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 03/29/2001 | WO2001021184A1 Cell-based gene therapy for the pulmonary system |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021162A2 Treating allergic and inflammatory conditions using desloratadine |
| 03/29/2001 | WO2001000612A3 Respiratory syncytial virus replication inhibitors |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000061233A3 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist |
| 03/29/2001 | WO2000061232A3 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist |
| 03/29/2001 | WO2000061182A3 Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2387520A1 Amine derivatives |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385447A1 Pyrazole derivatives |
| 03/29/2001 | CA2385404A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | CA2385047A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383214A1 Treating allergic and inflammatory conditions |
| 03/29/2001 | CA2383093A1 Cell-based gene therapy for the pulmonary system |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/29/2001 | CA2350700A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 03/28/2001 | EP1086688A1 Suspension aerosol formulations |
| 03/28/2001 | EP1086232A1 A vaccine-induced hepatitis b viral strain and uses thereof |
| 03/28/2001 | EP1086106A1 Furopyridine derivatives and their therapeutical use |
| 03/28/2001 | EP1086096A1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 03/28/2001 | EP1086085A1 INHIBITORS OF p38 |
| 03/28/2001 | EP1086081A1 Quarternary ammonium compounds as anti-tussive agents |
| 03/28/2001 | EP1086079A1 Derivatives of hydroxyphenylsulfanylbenzoic and hydroxyphenylsulfanylarylacetic acids |
| 03/28/2001 | EP1086066A1 Muscarinic receptor antagonists |
| 03/28/2001 | EP1085895A1 Bradykinin antagonists |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085877A1 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma |
| 03/28/2001 | EP1085872A1 INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B |
| 03/28/2001 | EP1085871A1 QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 03/28/2001 | EP1085868A1 H1-histamine receptor antagonists |
| 03/28/2001 | EP1085848A2 Inhibitors of transcription factor nf-kappa b |
| 03/28/2001 | EP1085847A2 Novel therapeutic agents that modulate estrogen receptors |
| 03/28/2001 | EP0775132B1 (azetidin-1-ylalkyl)lactams as tachykinin antagonists |
| 03/28/2001 | CN1289341A Thrombin inhibitors |
| 03/28/2001 | CN1289338A 2-(purin-9-yl)-tetahydrofuran-3,4-diol derivatives |
| 03/28/2001 | CN1289336A Chemokine receptor antagonists and methods of use therefor |
| 03/28/2001 | CN1289334A Benzothiadiazoles and derivatives |
| 03/28/2001 | CN1289322A Hydroxamic and carboxylic acid derivatives |
| 03/28/2001 | CN1289249A Derivatives of 1,3,4-oxadiazolone |
| 03/28/2001 | CN1288885A Alkylating method of hindered sulfonic acid |
| 03/28/2001 | CN1288747A Composite medicine containing dihydromyricetrin |
| 03/28/2001 | CN1288727A Composite medicine for rhinitis and its application |
| 03/27/2001 | USRE37116 Nitrosated and nitrosylated compounds, and compositions and their use for treating respiratory disorders |
| 03/27/2001 | US6207703 Mucoadministering to airways formulation comprising antifungal agent to reduce or eliminate symptoms of asthma |
| 03/27/2001 | US6207687 Substituted imidazoles having cytokine inhibitory activity |
| 03/27/2001 | US6207686 Endothelin antagonists |
| 03/27/2001 | US6207683 Benzocycloheptathiophene compounds |
| 03/27/2001 | US6207678 Used for treating inflammatory disease such as arthritis, psoriasis, asthma or inflammatory bowel disease, central nervous system disorder such as anxiety, depression, dementia or psychosis, gastrointestinal disorders |
| 03/27/2001 | US6207646 Immunostimulatory nucleic acid molecules |
| 03/27/2001 | US6207449 Nucleotide sequence of gene; hybridization probes for detection; drug screening for bactericides, bacteriostats and antibiotics |
| 03/27/2001 | US6207195 Sodium 4-phenylbutyrate in solid nanosphere formed by coacervation of a polycation, i.e., a protein and a polyanion, i.e., a nucleic acid; treatment of cystic fibrosis |
| 03/27/2001 | CA2104196C Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
| 03/27/2001 | CA2076540C Recombinant antibodies specific for tnf-.alpha. |
| 03/27/2001 | CA2065860C Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix |
| 03/22/2001 | WO2001020031A2 Polymorphisms in a klotho gene |
| 03/22/2001 | WO2001019973A2 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | WO2001019960A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 03/22/2001 | WO2001019901A2 Process for making aqueous coated beadlets |
| 03/22/2001 | WO2001019829A2 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | WO2001019826A2 Triazolopyrimidine derivatives |
| 03/22/2001 | WO2001019824A2 New active marine alkaloids |
| 03/22/2001 | WO2001019819A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019818A1 Phthalazinone derivatives as pd3/4 inhibitors |
| 03/22/2001 | WO2001019816A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 03/22/2001 | WO2001019809A1 Tryptase inhibitors |
| 03/22/2001 | WO2001019808A1 Chemical compounds and compositions and their use as cathepsin s inhibitors |
| 03/22/2001 | WO2001019796A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/22/2001 | WO2001019392A1 Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| 03/22/2001 | WO2001019382A1 Pharmaceutical composition that contains eucalyptus and orange oil |
| 03/22/2001 | WO2001019369A1 Use of thienopyrimidines |
| 03/22/2001 | WO2001019367A1 Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 03/22/2001 | WO2001019342A2 Pharmaceutical formulation of fluticasone propionate |
| 03/22/2001 | WO2001019341A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | WO2001019338A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 03/22/2001 | WO2001019322A2 Use of csaids in rhinovirus infection |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001019161A2 ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-β EXPRESSION |
| 03/22/2001 | WO2001000811A3 17867, a novel human aminopeptidase |
| 03/22/2001 | WO2000069255A8 Anti-inflammatory therapy for inflammatory mediated infection |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |
| 03/22/2001 | WO2000030607A8 PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134a |
| 03/22/2001 | WO2000018421A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |